Psoriasis Drugs Market

Market Definition

Psoriasis drugs are medications used to treat psoriasis, a chronic autoimmune skin condition that causes inflammation, redness, and scaling. The market includes a range of therapies such as biologics, topical agents, and systemic treatments aimed at managing symptoms and preventing flare-ups.

These drugs are applied in clinical and home settings to improve skin health, reduce inflammation, and enhance the quality of life for individuals affected by moderate to severe psoriasis.

Psoriasis Drugs Market Overview

The global psoriasis drugs market size was valued at USD 19.39 billion in 2024 and is projected to grow from USD 21.15 billion in 2025 to USD 40.96 billion by 2032, exhibiting a CAGR of 9.68% during the forecast period.

The growth of the market is driven by a rising geriatric population and increasing demand for long-term, safe treatments tailored to age-related immune decline. Additionally, Innovation in biologics targeting advanced pathways is shaping the long-term management of chronic, resistant cases.

Major companies operating in the psoriasis drugs industry are Johnson & Johnson Services, Inc., Eli Lilly and Company, UCB S.A., AbbVie, Merck & Co., Inc., Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals UK Limited, Pfizer Inc., LEO Pharma A/S, Sun Pharmaceutical Industries Limited, Arcutis Biotherapeutics, Inc, Biogen, Bristol-Myers Squibb Company, and Sanofi.

The market is driven by the rising global prevalence of psoriasis, which is increasing the demand for effective and accessible treatment options. With increasing prevalence rates in regions like Asia, Europe, and the Middle East, the expanding patient pool is prompting healthcare providers to prioritize dermatological care.

This growth is compelling pharmaceutical companies to invest in innovative therapies, expand geographic reach, and enhance patient engagement strategies to meet the evolving treatment needs of a diverse global population.

• In March 2025, the National Institute of Health reported a global psoriasis prevalence of 4.4%. The prevalence was highest in Asia, reaching 5.7%, followed by the Middle East (4.9%) and Europe (4.6%). Lower rates were observed in Africa (1.7%) and North America (3.7%) compared to other regions. Urban populations and fair-skinned individuals reported higher prevalence compared to those in semi-urban or rural areas and individuals with darker skin tones.

Key Highlights:

1. The psoriasis drugs industry size was recorded at USD 19.39 billion in 2024.
2. The market is projected to grow at a CAGR of 9.68% from 2025 to 2032.
3. North America held a market share of 34.09% in 2024, with a valuation of USD 6.61 billion.
4. The tumor necrosis factor inhibitors segment garnered USD 5.44 billion in revenue in 2024.
5. The topical segment is expected to reach USD 17.09 billion by 2032.
6. The parenteral segment is anticipated to witness the fastest CAGR of 10.24% during the forecast period.
7. Asia Pacific is anticipated to grow at a CAGR of 10.70% during the forecast period.

Market Driver

Growing Geriatric Population

The psoriasis drugs market is driven by the increasing geriatric population, which is more susceptible to immune-mediated disorders such as psoriasis. Age-related decline in immune function leads to prolonged disease activity and more frequent flare-ups in older adults. This rising patient segment is creating greater demand for safe, long-term treatment options tailored to their health needs.

As the global elderly population expands, the market is experiencing increased pressure to provide therapies that address both efficacy and comorbidity management in aging individuals.

• In June 2024, the United Nations Population Fund reported that the global population aged 65 nearly doubled from 5.5% to 10.3% and is projected to reach 20.7% by 2074. Additionally, the number of people aged 80 and above is expected to more than triple, highlighting a clear shift toward aging demographics and reinforcing the need for chronic disease management solutions.

Market Challenge

Limited Long-Term Efficacy and Relapse Risk

The psoriasis drugs market faces a significant challenge due to limited long-term efficacy and the risk of disease relapse. Many existing therapies, especially topical and systemic drugs, provide temporary relief but fail to sustain long-term disease control. Patients often experience symptom recurrence after treatment discontinuation, impacting quality of life and treatment satisfaction.

To address this, companies are investing in next-generation biologics and small molecule inhibitors with extended durability and fewer side effects. Clinical research is increasingly focused on achieving long-lasting immune modulation, while firms are also exploring maintenance dosing strategies and personalized treatment plans to enhance long-term disease management and reduce relapse rates.

Market Trend 

Advancements in Biologic Therapies

A key trend shaping the psoriasis drugs market is the continued development of biologic therapies that target specific immune pathways. These treatments offer improved outcomes for patients with moderate to severe psoriasis, especially those unresponsive to conventional options. Biologics provide durable skin clearance with favorable safety profiles, supporting their growing adoption for long-term disease management.

• In October 2024, Innovent Biologics reported positive Phase 2 results for picankibart, an IL-23p19-targeted biologic, in patients with moderate to severe plaque psoriasis who had not responded to previous biologic treatments. After 16 weeks, 64.6% of patients achieved clear or nearly clear skin. These results highlight the potential of picankibart in long-term disease management and reinforce the growing importance of biologics in the evolving psoriasis drugs.

Psoriasis Drugs Market Report Snapshot

Segmentation	Details
By Class	Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, Others
By Treatment	Topical, Systemic, Biologics
By Route of Administration	Oral, Parenteral
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation:

• By Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, and Others): The tumor necrosis factor inhibitors segment earned USD 5.44 billion in 2024 due to their established efficacy in managing moderate to severe psoriasis and widespread adoption as first-line biologic therapies.
• By Treatment (Topical, Systemic, and Biologics): The topical segment held 42.17% of the market in 2024, due to its widespread use as a first-line, cost-effective treatment for mild to moderate psoriasis with minimal systemic side effects.
• By Route of Administration (Oral, and Parenteral): The oral segment is projected to reach USD 24.71 billion by 2032, owing to the growing demand for convenient, patient-friendly treatment options and the increasing availability of effective small-molecule therapies.

Psoriasis Drugs Market Regional Analysis

Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

North America psoriasis drugs market share stood at 34.09% in 2024 in the global market, with a valuation of USD 6.61 billion. The region dominates the market due to its strong clinical research ecosystem and rapid regulatory approvals. Moreover, a well-established framework for conducting pediatric and adult clinical trials is accelerating data generation and supporting early therapeutic validation.

In addition, regulatory bodies in this region enable timely review and approval of advanced treatments, ensuring swift access to underserved populations. This integrated approach strengthens North America's leadership in delivering innovative, evidence-based psoriasis therapies across diverse patient groups, thereby driving market growth in this region.

• In August 2024, Amgen announced the availability of Otezla (apremilast) in the U.S. for pediatric use. The Food and Drug Administration (FDA) approved the drug for treating moderate to severe plaque psoriasis in children aged 6 and older, weighing at least 20 kg, who require phototherapy or systemic therapy. It remains the only FDA-approved oral treatment for this pediatric patient segment.

Asia Pacific psoriasis drugs industry is poised for significant growth at a robust CAGR of 10.70% over the forecast period. The growth of the market in Asia Pacific is driven by improved healthcare infrastructure, which is enhancing access to dermatological care and advanced treatments. The expansion of hospitals, clinics, and specialized dermatology centers is enabling timely diagnosis and effective disease management.

Governments and private sectors are investing in healthcare modernization, particularly in emerging economies, to bridge urban-rural gaps. This advancement is facilitating the wider availability of biologics and systemic therapies, driving increased treatment adoption across diverse patient populations in the region.

Regulatory Frameworks

• In the U.S., the Food and Drug Administration (FDA) regulates psoriasis drugs. The FDA oversees the approval, safety, efficacy, labeling, and marketing of all pharmaceutical products, including biologics and systemic therapies used for treating psoriasis.
• In India, the regulation of psoriasis drugs is overseen by the Central Drugs Standard Control Organization (CDSCO), which operates under the Ministry of Health and Family Welfare to ensure the safety, efficacy, and quality of pharmaceutical products.
• In Europe, psoriasis drugs are regulated by the European Medicines Agency (EMA), which evaluates the safety, efficacy, and quality of medicines for human use.

Competitive Landscape

Companies in the psoriasis drugs industry are actively pursuing strategic initiatives such as mergers and acquisitions, product launches, and collaborative agreements to strengthen their market position. Key players are expanding their portfolios through biosimilar introductions, targeting underserved patient segments, and entering high-growth regions.

Continuous investments in late-stage clinical pipelines and regulatory filings further reflect their commitment to accelerating commercialization timelines and reinforcing their competitive edge in a rapidly evolving therapeutic landscape.

• In February 2025, Teva Pharmaceuticals and Alvotech announced the launch of SELARSDI (ustekinumab-aekn), a Stelara biosimilar, for multiple conditions including plaque psoriasis and pediatric psoriatic diseases. As the second biosimilar under their partnership, SELARSDI strengthens biosimilar availability in the market, enhancing treatment access and expanding therapeutic options for both adult and pediatric patients with inflammatory conditions.

List of Key Companies in Psoriasis Drugs Market:

• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• UCB S.A.
• AbbVie
• Merck & Co., Inc.
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Novartis Pharmaceuticals UK Limited
• Pfizer Inc.
• LEO Pharma A/S
• Sun Pharmaceutical Industries Limited
• Arcutis Biotherapeutics, Inc
• Biogen
• Bristol-Myers Squibb Company
• Sanofi

Recent Developments (Product Launch)

• In March 2025, Johnson & Johnson announced new data from its Phase 3 program for icotrokinra (JNJ-2113), an investigational oral peptide therapy designed to block the IL-23 receptor. The company also launched a head-to-head clinical trial comparing icotrokinra with ustekinumab, an approved monoclonal antibody used to treat moderate-to-severe plaque psoriasis. This development aims to evaluate whether the oral candidate can match or exceed the efficacy of existing injectable biologics, potentially offering a more convenient treatment option for patients.
• In February 2025, Samsung Bioepis launched PYZCHIVA (ustekinumab-ttwe), for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. PYZCHIVA will be commercialized through Sandoz, in multiple formulations, including pre-filled syringes, subcutaneous vials, and intravenous infusion vials, expanding treatment accessibility across approved indications.
• In September 2024, Arcutis Biotherapeutics launched ZORYVE (roflumilast) foam 0.3%, a once-daily next-generation PDE4 inhibitor, following FDA approval of its sNDA. The product is indicated for the treatment of scalp and body psoriasis in adults and adolescents aged 12 and older, expanding therapeutic options for hard-to-treat areas in moderate to severe psoriasis management.